2026 Jedd D. Wolchok: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Best Scientists	177	660	604	414	370	846	205075
Immunology	181	32	30	21	20	828	221850
Medicine	181	350	317	219	196	838	221861

Research.com Recognitions

2026 - Research.com Immunology in United States Leader Award
2025 - Research.com Best Scientists Award
2025 - Research.com Immunology in United States Leader Award
2023 - Research.com Medicine in United States Leader Award
Member of the Association of American Physicians
Member of the Association of American Physicians
Member of the Association of American Physicians
Member of the Association of American Physicians
Member of the Association of American Physicians

Overview

Jedd D. Wolchok is affiliated with Cornell University in the United States and focuses primarily on research in medicine, biochemistry, genetics, and molecular biology. Their work is concentrated in oncology, immunology, molecular biology, cancer research, and genetics, reflecting an interdisciplinary approach to understanding and treating cancer.

Their research covers several main topics, including:

Cancer Immunotherapy and Biomarkers
CAR-T cell therapy research
Immunotherapy and Immune Responses
Melanoma and MAPK Pathways
Immune cells in cancer
Cancer Genomics and Diagnostics
Immune Cell Function and Interaction

Jedd D. Wolchok has authored numerous publications with frequent appearance in these venues:

Cancer Research
Regular and Young Investigator Award Abstracts
Journal of Clinical Oncology
bioRxiv (Cold Spring Harbor Laboratory)
Cancer Cell

They have collaborated extensively with several coauthors in the field, including:

Taha Merghoub
Sadna Budhu
Roberta Zappasodi
Michael A. Postow
Levi Mangarin

Recent papers authored or coauthored by Jedd D. Wolchok provide insights into cancer immunotherapy and its implementation:

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer, 2023, Nature
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways, 2021, Nature Reviews Clinical Oncology
Clinical implications of T cell exhaustion for cancer immunotherapy, 2022, Nature Reviews Clinical Oncology
The future of cancer immunotherapy: microenvironment-targeting combinations, 2020, Cell Research
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors, 2021, Immunity

The scientist is recognized as a member of the Association of American Physicians, an acknowledgment of professional contribution to medical science.

Best Publications

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

17411
Citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg

8455
Citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

8404
Citations
Cancer immunotherapy using checkpoint blockade

Antoni Ribas;Jedd D. Wolchok;Jedd D. Wolchok

6368
Citations
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

5418
Citations
Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

5005
Citations
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

4954
Citations
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan

4702
Citations
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

4127
Citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

4125
Citations
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

Héctor Peinado;Maša Alečković;Simon Lavotshkin;Irina Matei

4062
Citations
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

3875
Citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

3808
Citations
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber

3730
Citations
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov

3201
Citations
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

3127
Citations
Immune Checkpoint Blockade in Cancer Therapy

Michael A. Postow;Margaret K. Callahan;Jedd D. Wolchok

3040
Citations
Antibody therapy of cancer

Andrew M. Scott;Jedd D. Wolchok;Lloyd J. Old;Lloyd J. Old

2649
Citations
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Weiping Zou;Jedd D. Wolchok;Lieping Chen

2484
Citations
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Lesley Seymour;Jan Bogaerts;Andrea Perrone;Robert Ford

2369
Citations
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber

2245
Citations

Frequent Co-Authors

Taha Merghoub Cornell University

Michael A. Postow Memorial Sloan Kettering Cancer Center

Alan N. Houghton Memorial Sloan Kettering Cancer Center

Paul B. Chapman Memorial Sloan Kettering Cancer Center

F. Stephen Hodi Harvard University

Jianda Yuan MSD (United States)

Katherine S. Panageas Memorial Sloan Kettering Cancer Center

Caroline Robert University of Paris-Saclay

James P. Allison The University of Texas MD Anderson Cancer Center

Matthew D. Hellmann Memorial Sloan Kettering Cancer Center

External Links

Personal website of Jedd D. Wolchok Google Scholar page

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens numerous doors in healthcare and research, but many students consider complementary pathways to broaden their expertise. For those interested in advancing clinical skills, transitioning from a Family Nurse Practitioner to a specialized role can be appealing. Exploring how to fnp to acute care np offers insights into more focused patient care opportunities in acute settings.

For individuals without a nursing background eager to enter the field quickly, online options like online bsn programs for non nurses provide a streamlined route. These programs are designed for career changers and emphasize flexibility and accessibility, making them ideal for busy students or professionals.

If you already hold a degree but want to expedite your nursing education, looking into 12-month accelerated nursing programs can be beneficial. These intensive pathways dramatically shorten the time to enter the nursing workforce while maintaining quality education.

Finally, for those ready to fast-track clinical practice, researching the accelerated np programs online reveals accelerated routes to becoming a Nurse Practitioner, combining convenience with rigorous training. Together, these options help shape diverse career trajectories closely linked to Immunology studies.